Core Viewpoint - Sonder Holdings Inc. announced the resignation of Chief Financial Officer Michael Hughes, effective August 15, 2025, while the search for a new CEO is ongoing, with expectations to appoint a permanent successor by the end of 2025 [1][2]. Company Overview - Sonder is a leading global brand offering premium, design-forward apartments and boutique hotels, catering to modern travelers since its launch in 2014 [2]. - The company operates in over 40 markets across nine countries and three continents, providing tech-enabled services and self-service features through the Sonder app [2]. Leadership Transition - The interim CEO, Janice Sears, expressed gratitude for Michael Hughes' contributions and emphasized the importance of identifying world-class executives to maximize Sonder's growth potential [2]. - The new CEO will be actively involved in the search for a new CFO as part of the long-term leadership succession plan [1][2].

Core Insights - Reviva Pharmaceuticals is advancing its brilaroxazine program towards potential registration, with a planned meeting with the FDA in Q4 2025 to discuss the New Drug Application (NDA) submission targeted for Q2 2026 [2][5] Clinical Program and Business Highlights - The company successfully completed a 1-year open-label extension (OLE) trial for brilaroxazine, demonstrating a well-tolerated safety profile and robust broad-spectrum efficacy across all symptom domains in schizophrenia [1][5] - Brilaroxazine showed a significant reduction in PANSS total score by 18.1, positive symptoms by 5.0, and negative symptoms by 4.4, with a discontinuation rate of 35% after 1 year [5] - Reviva is expanding its patent portfolio, aiming for potential patent and market exclusivity up to 2045 and beyond [5] - A late-breaking poster presentation on the RECOVER 12-month OLE trial was presented at the 2025 ASCP annual meeting [5] Financial Results - For the second quarter ended June 30, 2025, the company reported a net loss of approximately $6.1 million, or $0.12 per share, compared to a net loss of approximately $7.9 million, or $0.26 per share, for the same period in 2024 [10][13] - As of June 30, 2025, cash and cash equivalents totaled approximately $10.4 million, down from approximately $13.5 million as of December 31, 2024 [10][11] Anticipated Milestones and Events - The company plans to initiate a potential registrational Phase 3 RECOVER-2 trial for brilaroxazine pending FDA recommendations [5] - An IND submission for a liposomal-gel formulation of brilaroxazine in psoriasis is expected by Q2 2026 [10]

Breton Hill by Toll Brothers will feature only 13 new homes on up to one-acre home sites with serene views in historic Warwick TownshipFORT WASHINGTON, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Bucks County community, Breton Hill by Toll Brothers, is coming soon to Warwick Township, Pennsylvania. Site work is underway, and the community is expected to open for sale in late 2025. Located in sought-after Warw ...

Core Insights - Eledon Pharmaceuticals reported positive data from an ongoing Phase 1b trial of tegoprubart, showing a mean 12-month estimated glomerular filtration rate (eGFR) of approximately 68 mL/min/1.73 m for kidney transplant patients, significantly higher than the historical mean of 53 mL/min/1.73 m with standard care [1][3] - The company is on track to release topline results from the Phase 2 BESTOW trial in kidney transplantation in November 2025 [1][10] - Eledon has a cash position of $107.6 million as of June 30, 2025, which is expected to fund operations through the end of 2026 [1][5] Business Highlights - Eledon achieved key milestones in advancing tegoprubart for kidney, islet cell, and liver transplantation, as well as xenotransplantation [2] - Updated data presented at the World Transplant Congress indicated that tegoprubart was well tolerated with no severe adverse events reported [3] - The company announced the first three islet cell transplant recipients treated with tegoprubart at the University of Chicago, achieving insulin independence [3] Financial Results - Research and development expenses for Q2 2025 were $20.3 million, up from $10.1 million in Q2 2024 [6] - General and administrative expenses for Q2 2025 were $4.5 million, slightly higher than $4.4 million in Q2 2024 [7] - The net loss for Q2 2025 was $11.2 million, a significant reduction from a net loss of $44.9 million in Q2 2024 [7][16] Upcoming Milestones - The company plans to report topline results from the Phase 2 BESTOW trial in November 2025 [10] - Eledon will launch an investigator-initiated trial at Massachusetts General Hospital to evaluate tegoprubart for inducing donor-specific immune tolerance [10]

~ Q2 Gross Margin Expansion, Cost Reductions, Strategic Transactions, and Diversified Revenue Initiatives Could Position Super League to Achieve Adjusted EBITDA Positive in Q4 ~ ~ Company Advances Key Financial Initiatives and Broadens Revenue Mix ~ SANTA MONICA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE), a leader in engaging audiences through playable media, content, and experiences within mobile games and the world’s largest immersive platforms, today released second quarter 202 ...

Core Insights - Ocean Power Technologies, Inc. (OPT) is actively participating in shaping the future of marine energy in New Jersey through a joint hearing with state lawmakers, emphasizing the importance of tidal and wave energy [1][2] - The company’s proprietary technologies, including PowerBuoy systems and WAM-V autonomous surface vehicles, are positioned to provide clean energy and environmental monitoring, showcasing New Jersey's potential as a leader in the marine energy sector [2][4] Company Developments - OPT recently achieved a significant milestone with the installation of an AI-capable Merrows™ PowerBuoy for the Naval Postgraduate School, integrating advanced technology for continuous monitoring and real-time data applications [3] - The company’s President and CEO, Philipp Stratmann, highlighted the strategic advantages of New Jersey, including its coastline and industrial base, which could support a global leadership position in marine energy if backed by appropriate policies [2][4] Industry Context - Stratmann called for accelerated actions from lawmakers to foster industry collaboration and enable real-world testing within state waters, which could drive innovation and create high-value jobs while enhancing climate resilience and national security [4] - OPT's offerings include intelligent maritime solutions that cater to various sectors such as defense, oil and gas, and offshore wind, indicating a broad market application for its technologies [6]

Core Viewpoint - KULR Technology Group is positioned for growth with strong financial results in Q2 2025, driven by increased revenues and significant Bitcoin holdings, enabling further investments in product development and R&D efforts [2][6][7]. Financial Performance - Revenues for Q2 2025 increased by 63% to $3.97 million compared to $2.43 million in Q2 2024, with product sales rising by 74% to approximately $1.98 million [2]. - As of June 30, 2025, the company had cash and current accounts receivable totaling $24.73 million [3]. - Gross margin decreased to 18% in Q2 2025 from 24% in the same period last year, attributed to unexpected labor hours for technical projects [3]. - Selling, General and Administrative (SG&A) expenses rose to $6.94 million from $4.59 million year-over-year, mainly due to increased advertising, marketing, and stock-based compensation [4]. - Research and Development (R&D) expenses increased to $2.44 million from $1.31 million, reflecting a planned rise in consulting services [5]. - Operating loss for Q2 2025 was $9.45 million, up from $5.33 million in Q2 2024, driven by higher SG&A and R&D investments [5]. - Net income for Q2 2025 was $8.14 million, or $0.22 per share, compared to a net loss of $5.89 million, or a loss of $0.26 per share in the same period last year, primarily due to a mark-to-market gain on Bitcoin holdings [6]. Corporate Developments - KULR joined the Russell 3000® Index effective June 30, 2025, enhancing its market visibility [8]. - The company expanded its Bitcoin holdings to 1,021 BTC, achieving a yield of 291.2% [9]. - KULR secured a $20 million credit facility with Coinbase to support its Bitcoin acquisition strategy [10]. - A reverse stock split of 1-for-8 was completed on June 23, 2025, reducing outstanding shares from approximately 300 million to 40 million [10]. - KULR's Bitcoin mining operations reached 750 PH/s with plans to increase to 1.25 EH/s by late summer [10].

Financial Performance - Net sales for the three months ended June 30, 2025, were $2.56 million, a decrease of 5% from $2.69 million in the same period of 2024 [5] - Gross profit for the same period was $1.28 million compared to $1.19 million in the same period of 2024 [5] - Net loss for the three months was ($289 thousand), an improvement from a loss of ($536 thousand) in the same period of 2024 [5] - For the six months ended June 30, 2025, net sales were $5.19 million, an increase of 3% from $5.06 million in the same period of 2024 [5] - Gross profit for the six months was $2.49 million, compared to $2.21 million in the same period of 2024 [5] - Net loss for the six months was ($629 thousand), significantly improved from a loss of ($2.03 million) in the same period of 2024 [5] Industry Outlook - The company acknowledges potential volatility in the furniture industry in the short term but believes it is well-positioned to meet customer needs [1] - The company is encouraged by incoming purchase orders and ongoing discussions with buyers, leading to increased advances to suppliers to maintain adequate inventory levels for the second half of the year [1]

Company Overview - CooperCompanies is a leading global medical device company with a focus on enhancing people's experiences through its two business units: CooperVision and CooperSurgical [2] - CooperVision is a prominent player in the contact lens industry, while CooperSurgical specializes in fertility and women's healthcare [2] - The company is headquartered in San Ramon, California, employs over 16,000 people, and sells products in more than 130 countries, positively impacting over 50 million lives annually [2] Upcoming Events - CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025, with President and CEO Al White representing the company [1] - The session is scheduled for 3:00 PM ET, and a webcast will be available for investors and interested parties [1]

Core Insights - Itron, Inc. has appointed Sheri Savage, former CFO of Ultra Clean Holdings, to its board of directors, effective August 11, 2025, bringing over 30 years of finance experience [1][2]. Company Overview - Itron is focused on innovating solutions for utilities and cities to manage energy and water, aiming to improve efficiency and deliver reliable services [5]. Leadership Experience - Sheri Savage has held multiple leadership roles at Ultra Clean Holdings since 2009, becoming CFO in 2016 and leading the company through significant revenue and earnings growth [2]. - Prior to her role at UCT, Savage served as corporate controller and vice president of finance at Credence Systems Corporation, and held various roles at Protiviti and KLA-Tencor Corporation [2]. Board Expectations - The chair of Itron's board, Diana Tremblay, highlighted Savage's strategic financial leadership and extensive experience in various financial domains as key qualifications for her board position [3]. - Itron's CEO, Tom Deitrich, expressed confidence that Savage's experience in public company finance will be beneficial for advancing the company's business strategy and enhancing shareholder value [4].